BeiGene, Ltd. (ONC)vsUniqure NV (QURE)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
QURE
Uniqure NV
$16.36
+7.77%
HEALTHCARE · Cap: $949.20M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 33091% more annual revenue ($5.34B vs $16.10M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
QURE
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for QURE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -2.1% — below average capital efficiency
Earnings declined 18.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : QURE
QURE has a balanced fundamental profile.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : QURE
The primary concerns for QURE are Market Cap, Profit Margin, Return on Equity.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while QURE is a value play — different risk/reward profiles.
QURE carries more volatility with a beta of 0.77 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 22/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Uniqure NV
HEALTHCARE · BIOTECHNOLOGY · USA
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?